According to The Pharm Voice, Cobalis Corp. has begun clinical trials for PreHistin, a seasonal treatment for ragweed allergies. Approximately 2,000 patients in total will be randomized into the twin studies to receive either placebo or 3.3 mg sublingual PreHistin twice daily for three weeks prior to the onset of the ragweed allergy season, and for an additional three weeks into the allergy season.